Pharmacologic treatment improved mortality and quality of life in osteoporotic hip fracture without increasing cost: 12 months follow-up

摘要

Osteoporotic hip fracture is an important cause of mortality and morbidity among the elderly patients. The effect of osteoporotic treatment on mortality has not been carefully evaluated in real-life. Objective: To assess the effect of pharmacologic osteoporosis treatment on mortality and quality of life in osteoporotic hip fracture as well as evaluate the cost per quality adjusted life year (QALY) between patients who received pharmacologic osteoporosis treatment (treatment group) and who did not receive anti-osteoporotic drug (non-treatment group). Background: Osteoporotic hip fracture is an important cause of mortality and morbidity among the elderly patients. The effect of osteoporotic treatment on mortality has not been carefully evaluated in real-life.